Police & Firemen s Retirement System of New Jersey Has $280,000 Stake in 10x Genomics $TXG

Police & Firemen s Retirement System of New Jersey lowered its holdings in 10x Genomics (NASDAQ:TXG) by 35.3% in the second quarter, HoldingsChannel.com reports. The firm owned 24,181 shares of the company’s stock after selling 13,190 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in 10x Genomics were worth $280,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Allworth Financial LP grew its position in 10x Genomics by 150.4% during the second quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after buying an additional 1,364 shares in the last quarter. True Wealth Design LLC raised its holdings in 10x Genomics by 1,552.5% in the 2nd quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock valued at $42,000 after acquiring an additional 3,369 shares in the last quarter. Blue Trust Inc. lifted its position in shares of 10x Genomics by 48.1% during the 2nd quarter. Blue Trust Inc. now owns 4,894 shares of the company’s stock valued at $57,000 after acquiring an additional 1,590 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of 10x Genomics by 153.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company’s stock worth $45,000 after purchasing an additional 3,119 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of 10x Genomics by 314.5% in the first quarter. US Bancorp DE now owns 5,973 shares of the company’s stock worth $52,000 after purchasing an additional 4,532 shares during the period. 84.68% of the stock is owned by institutional investors.

10x Genomics Trading Down 1.7%

TXG opened at $18.75 on Friday. The company has a market cap of $2.37 billion, a P/E ratio of -30.24 and a beta of 2.13. The company’s 50 day moving average is $13.90 and its 200-day moving average is $12.60. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $20.34.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The business had revenue of $149.00 million during the quarter, compared to the consensus estimate of $142.50 million. During the same quarter in the prior year, the firm earned ($0.30) EPS. The firm’s revenue was down 1.7% compared to the same quarter last year. 10x Genomics has set its Q4 2025 guidance at EPS. On average, equities analysts forecast that 10x Genomics will post -1.43 EPS for the current year.

Insider Transactions at 10x Genomics

In related news, CFO Adam Taich sold 11,888 shares of 10x Genomics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $19.00, for a total transaction of $225,872.00. Following the sale, the chief financial officer directly owned 297,385 shares in the company, valued at $5,650,315. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 8,283 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $19.00, for a total transaction of $157,377.00. Following the completion of the transaction, the insider owned 432,605 shares of the company’s stock, valued at approximately $8,219,495. This trade represents a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 33,432 shares of company stock worth $635,208. Insiders own 9.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on TXG shares. Zacks Research downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Wall Street Zen lowered shares of 10x Genomics from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Deutsche Bank Aktiengesellschaft set a $14.00 price target on shares of 10x Genomics and gave the stock a “hold” rating in a report on Friday, August 8th. Barclays increased their price target on shares of 10x Genomics from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, Morgan Stanley lowered their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Tuesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $14.88.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.